You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Patent: 6,316,408


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,316,408
Title: Methods of use for osetoprotegerin binding protein receptors
Abstract:A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget\'s disease are also provided. Receptors for osteoprotegerin binding proteins are also described. The receptors, and agonists and antagonists thereof, may be used to treat bone diseases.
Inventor(s): Boyle; William J. (Moorpark, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:09/052,521
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of United States Patent 6,316,408: Claims and Patent Landscape

Introduction

United States Patent 6,316,408, hereafter referred to as the '408 patent, is a significant intellectual property asset that requires a thorough analysis to understand its claims, implications, and position within the broader patent landscape. This analysis will delve into the patent's claims, the legal and technical context, and the current state of relevant patent law and practices.

Background of the Patent

To begin, it is crucial to identify the subject matter of the '408 patent. While the specific details of this patent are not provided in the sources, a general approach to analyzing any patent involves understanding its invention, claims, and the technological field it pertains to.

Claims Analysis

Understanding Patent Claims

Patent claims are the heart of any patent, defining the scope of the invention and what is protected by the patent. These claims must be clear, concise, and supported by the patent's specification[3].

Types of Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit an independent claim.
  • Method Claims: These claims describe a process or method.
  • Apparatus Claims: These claims describe a physical device or system.

Claim Construction

The construction of claims is critical for determining the patent's scope. This involves interpreting the language of the claims in light of the specification, prosecution history, and any relevant extrinsic evidence[3].

Legal Context: Obviousness-Type Double Patenting (ODP)

The '408 patent must be considered in the context of current patent law, particularly the doctrine of obviousness-type double patenting (ODP). ODP prevents the granting of a subsequent patent that is an obvious modification of an earlier granted patent. This doctrine is crucial for ensuring that inventors do not extend the term of their patents indefinitely by filing multiple patents on the same or very similar inventions[2].

Terminal Disclaimers

To avoid ODP issues, patent owners may need to file terminal disclaimers, which disclaim the terminal portion of the patent term that would extend beyond the expiration date of an earlier issued patent. This ensures that the later patent does not improperly extend the term of the same invention[3].

Patent Term Adjustments and Extensions

Patent Term Adjustments (PTA)

The '408 patent may be subject to patent term adjustments (PTA) if delays during the prosecution process were caused by the USPTO. However, as seen in the In re Cellect case, PTA can interact complexly with ODP, potentially leading to the invalidation of claims if not properly managed[2].

Patent Term Extensions (PTE)

In addition to PTA, patents can also be subject to term extensions under certain conditions, such as premarket regulatory review. These extensions are separate from and added to any adjustments under 35 U.S.C. ยง 154[3].

International Patent Landscape

Global Patent Databases

The '408 patent exists within a global patent landscape. Tools like the PATENTSCOPE database and the European Patent Office's esp@cenet provide access to international patent applications and granted patents, allowing for comprehensive searches across multiple jurisdictions[1][4].

Machine Translation and Global Dossier

Modern tools offer machine translation capabilities for patent documents, facilitating international searches. The Global Dossier service also provides a unified view of related applications across different IP offices, aiding in the analysis of patent families and prior art[4].

Use of AI Tools in Patent Practice

Disclosure Requirements

The increasing use of AI tools in patent drafting and analysis introduces new complexities. Practitioners must disclose any material information related to AI contributions, ensuring that the inventorship and patentability of the invention are accurately represented[5].

Accuracy and Verification

AI-assisted documents must be verified for accuracy to avoid introducing inaccurate statements or omitting material information. This is crucial for maintaining the integrity of the patent application process[5].

Practical Implications and Strategies

Conducting Preliminary Searches

Before filing or enforcing a patent like the '408 patent, it is essential to conduct thorough preliminary searches using tools like the Patent Public Search and Global Dossier. These searches help identify prior art and potential ODP issues[1][4].

Training and Resources

Utilizing resources such as the USPTO's Patent and Trademark Resource Centers (PTRCs) and online tutorials can help practitioners navigate the complexities of patent searching and analysis[1][4].

Case Law and Precedents

In re Cellect

The In re Cellect case highlights the importance of addressing ODP during the prosecution phase. It emphasizes that patent owners must be proactive in filing terminal disclaimers to avoid invalidation of claims due to unjustified term extensions[2].

Key Takeaways

  • Claims Analysis: Understanding the claims of the '408 patent is crucial for determining its scope and validity.
  • ODP and Terminal Disclaimers: Ensuring compliance with ODP and filing terminal disclaimers are critical to avoid invalidation of claims.
  • Patent Term Adjustments and Extensions: Managing PTA and PTE correctly is vital to maintain the validity of the patent.
  • Global Patent Landscape: Utilizing global patent databases and tools like PATENTSCOPE and Global Dossier is essential for comprehensive searches.
  • AI Tools: Disclosing AI contributions and verifying accuracy are necessary to maintain the integrity of the patent application process.

FAQs

Q: What is the significance of terminal disclaimers in patent law?

A: Terminal disclaimers are used to disclaim the terminal portion of a patent term that would extend beyond the expiration date of an earlier issued patent, preventing obviousness-type double patenting issues.

Q: How do patent term adjustments (PTA) interact with obviousness-type double patenting?

A: PTA can lead to the invalidation of claims if it results in an unjustified extension of the patent term, as seen in the In re Cellect case.

Q: What resources are available for conducting international patent searches?

A: Resources include PATENTSCOPE, Global Dossier, and databases from various international intellectual property offices like the European Patent Office and the Japan Patent Office.

Q: Why is it important to disclose AI contributions in patent applications?

A: Disclosing AI contributions is necessary to ensure that the inventorship and patentability of the invention are accurately represented and to comply with USPTO guidelines.

Q: How can practitioners ensure the accuracy of AI-assisted patent documents?

A: Practitioners must verify the accuracy of factual assertions and ensure that AI-assisted documents do not introduce inaccurate statements or omit material information.

Sources

  1. Clemson University Libraries - Research and Course Guides: Patent Searching, Advanced[1].
  2. Mintz - Federal Circuit Puts the Onus on Patent Owners to Disclaim Patent[2].
  3. USPTO - Manual of Patent Examining Procedure (MPEP) - Patent Term[3].
  4. USPTO - Search for Patents[4].
  5. Buchanan Ingersoll & Rooney PC - U.S. Patent Office Issues Additional Guidance on Use of AI Tools[5].

More… ↓

⤷  Subscribe

Details for Patent 6,316,408

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Takeda Pharmaceuticals U.s.a., Inc. NATPARA parathyroid hormone For Injection 125511 January 23, 2015 ⤷  Subscribe 2017-04-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.